Milne D, Hyatt A, Billett A, et al. Understanding the impact of immunotherapy side effects on quality of life of patients with stage IV melanoma not on clinical trial: ‘Real world’ data to inform supportive care interventions. SMR2017, abstract P05-3.
Afatinib gevolgd door osimertinib bij EGFR-gemuteerd NSCLC
okt 2018 | Longoncologie